COVID-19 Impact on Global PD-1 and PD-L1 Inhibitors Market Size, Status and Forecast 2020-2026

August 2020 | 92 pages | ID: CCEB916612BAEN
QYResearch

Abstracts

This report focuses on the global PD-1 and PD-L1 Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PD-1 and PD-L1 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Merck
• Novartis
• Roche
• AstraZeneca
• Pfizer
• GlaxoSmithKline Plc
• Jiangsu HengRui Medicine Co.,Ltd
• Innovent + Eli Lilly
• Bristol Myers Squibb (BMS)

Market segment by Type, the product can be split into

• PD-1 Inhibitors
• PD-L1 Inhibitors

Market segment by Application, split into

• Advanced Melanoma
• Non-small Cell Lung Cancer (NSCLC)
• Renal Cell Carcinoma
• Bladder Cancer
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global PD-1 and PD-L1 Inhibitors status, future forecast, growth opportunity, key market and key players.
• To present the PD-1 and PD-L1 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of PD-1 and PD-L1 Inhibitors are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by PD-1 and PD-L1 Inhibitors Revenue
1.4 Market Analysis by Type
  1.4.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 PD-1 Inhibitors
  1.4.3 PD-L1 Inhibitors
1.5 Market by Application
  1.5.1 Global PD-1 and PD-L1 Inhibitors Market Share by Application: 2020 VS 2026
  1.5.2 Advanced Melanoma
  1.5.3 Non-small Cell Lung Cancer (NSCLC)
  1.5.4 Renal Cell Carcinoma
  1.5.5 Bladder Cancer
  1.5.6 Others
1.6 Coronavirus Disease 2019 (Covid-19): PD-1 and PD-L1 Inhibitors Industry Impact
  1.6.1 How the Covid-19 is Affecting the PD-1 and PD-L1 Inhibitors Industry
    1.6.1.1 PD-1 and PD-L1 Inhibitors Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and PD-1 and PD-L1 Inhibitors Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for PD-1 and PD-L1 Inhibitors Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 PD-1 and PD-L1 Inhibitors Market Perspective (2015-2026)
2.2 PD-1 and PD-L1 Inhibitors Growth Trends by Regions
  2.2.1 PD-1 and PD-L1 Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 PD-1 and PD-L1 Inhibitors Historic Market Share by Regions (2015-2020)
  2.2.3 PD-1 and PD-L1 Inhibitors Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 PD-1 and PD-L1 Inhibitors Market Growth Strategy
  2.3.6 Primary Interviews with Key PD-1 and PD-L1 Inhibitors Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top PD-1 and PD-L1 Inhibitors Players by Market Size
  3.1.1 Global Top PD-1 and PD-L1 Inhibitors Players by Revenue (2015-2020)
  3.1.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Players (2015-2020)
  3.1.3 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global PD-1 and PD-L1 Inhibitors Market Concentration Ratio
  3.2.1 Global PD-1 and PD-L1 Inhibitors Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Revenue in 2019
3.3 PD-1 and PD-L1 Inhibitors Key Players Head office and Area Served
3.4 Key Players PD-1 and PD-L1 Inhibitors Product Solution and Service
3.5 Date of Enter into PD-1 and PD-L1 Inhibitors Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global PD-1 and PD-L1 Inhibitors Historic Market Size by Type (2015-2020)
4.2 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Type (2021-2026)

5 PD-1 AND PD-L1 INHIBITORS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)
5.2 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
6.2 PD-1 and PD-L1 Inhibitors Key Players in North America (2019-2020)
6.3 North America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
6.4 North America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
7.2 PD-1 and PD-L1 Inhibitors Key Players in Europe (2019-2020)
7.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
7.4 Europe PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

8 CHINA

8.1 China PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
8.2 PD-1 and PD-L1 Inhibitors Key Players in China (2019-2020)
8.3 China PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
8.4 China PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
9.2 PD-1 and PD-L1 Inhibitors Key Players in Japan (2019-2020)
9.3 Japan PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
9.4 Japan PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
10.2 PD-1 and PD-L1 Inhibitors Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
10.4 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

11 INDIA

11.1 India PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
11.2 PD-1 and PD-L1 Inhibitors Key Players in India (2019-2020)
11.3 India PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
11.4 India PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America PD-1 and PD-L1 Inhibitors Market Size (2015-2020)
12.2 PD-1 and PD-L1 Inhibitors Key Players in Central & South America (2019-2020)
12.3 Central & South America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020)
12.4 Central & South America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Merck
  13.1.1 Merck Company Details
  13.1.2 Merck Business Overview and Its Total Revenue
  13.1.3 Merck PD-1 and PD-L1 Inhibitors Introduction
  13.1.4 Merck Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020))
  13.1.5 Merck Recent Development
13.2 Novartis
  13.2.1 Novartis Company Details
  13.2.2 Novartis Business Overview and Its Total Revenue
  13.2.3 Novartis PD-1 and PD-L1 Inhibitors Introduction
  13.2.4 Novartis Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.2.5 Novartis Recent Development
13.3 Roche
  13.3.1 Roche Company Details
  13.3.2 Roche Business Overview and Its Total Revenue
  13.3.3 Roche PD-1 and PD-L1 Inhibitors Introduction
  13.3.4 Roche Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.3.5 Roche Recent Development
13.4 AstraZeneca
  13.4.1 AstraZeneca Company Details
  13.4.2 AstraZeneca Business Overview and Its Total Revenue
  13.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Introduction
  13.4.4 AstraZeneca Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.4.5 AstraZeneca Recent Development
13.5 Pfizer
  13.5.1 Pfizer Company Details
  13.5.2 Pfizer Business Overview and Its Total Revenue
  13.5.3 Pfizer PD-1 and PD-L1 Inhibitors Introduction
  13.5.4 Pfizer Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.5.5 Pfizer Recent Development
13.6 GlaxoSmithKline Plc
  13.6.1 GlaxoSmithKline Plc Company Details
  13.6.2 GlaxoSmithKline Plc Business Overview and Its Total Revenue
  13.6.3 GlaxoSmithKline Plc PD-1 and PD-L1 Inhibitors Introduction
  13.6.4 GlaxoSmithKline Plc Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.6.5 GlaxoSmithKline Plc Recent Development
13.7 Jiangsu HengRui Medicine Co.,Ltd
  13.7.1 Jiangsu HengRui Medicine Co.,Ltd Company Details
  13.7.2 Jiangsu HengRui Medicine Co.,Ltd Business Overview and Its Total Revenue
  13.7.3 Jiangsu HengRui Medicine Co.,Ltd PD-1 and PD-L1 Inhibitors Introduction
  13.7.4 Jiangsu HengRui Medicine Co.,Ltd Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.7.5 Jiangsu HengRui Medicine Co.,Ltd Recent Development
13.8 Innovent + Eli Lilly
  13.8.1 Innovent + Eli Lilly Company Details
  13.8.2 Innovent + Eli Lilly Business Overview and Its Total Revenue
  13.8.3 Innovent + Eli Lilly PD-1 and PD-L1 Inhibitors Introduction
  13.8.4 Innovent + Eli Lilly Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.8.5 Innovent + Eli Lilly Recent Development
13.9 Bristol Myers Squibb (BMS)
  13.9.1 Bristol Myers Squibb (BMS) Company Details
  13.9.2 Bristol Myers Squibb (BMS) Business Overview and Its Total Revenue
  13.9.3 Bristol Myers Squibb (BMS) PD-1 and PD-L1 Inhibitors Introduction
  13.9.4 Bristol Myers Squibb (BMS) Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)
  13.9.5 Bristol Myers Squibb (BMS) Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. PD-1 and PD-L1 Inhibitors Key Market Segments
Table 2. Key Players Covered: Ranking by PD-1 and PD-L1 Inhibitors Revenue
Table 3. Ranking of Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of PD-1 Inhibitors
Table 6. Key Players of PD-L1 Inhibitors
Table 7. COVID-19 Impact Global Market: (Four PD-1 and PD-L1 Inhibitors Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for PD-1 and PD-L1 Inhibitors Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for PD-1 and PD-L1 Inhibitors Players to Combat Covid-19 Impact
Table 12. Global PD-1 and PD-L1 Inhibitors Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global PD-1 and PD-L1 Inhibitors Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global PD-1 and PD-L1 Inhibitors Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global PD-1 and PD-L1 Inhibitors Market Share by Regions (2015-2020)
Table 16. Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global PD-1 and PD-L1 Inhibitors Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. PD-1 and PD-L1 Inhibitors Market Growth Strategy
Table 22. Main Points Interviewed from Key PD-1 and PD-L1 Inhibitors Players
Table 23. Global PD-1 and PD-L1 Inhibitors Revenue by Players (2015-2020) (Million US$)
Table 24. Global PD-1 and PD-L1 Inhibitors Market Share by Players (2015-2020)
Table 25. Global Top PD-1 and PD-L1 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 and PD-L1 Inhibitors as of 2019)
Table 26. Global PD-1 and PD-L1 Inhibitors by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players PD-1 and PD-L1 Inhibitors Product Solution and Service
Table 29. Date of Enter into PD-1 and PD-L1 Inhibitors Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 32. Global PD-1 and PD-L1 Inhibitors Market Size Share by Type (2015-2020)
Table 33. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2026)
Table 34. Global PD-1 and PD-L1 Inhibitors Market Size Share by Application (2015-2020)
Table 35. Global PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 36. Global PD-1 and PD-L1 Inhibitors Market Size Share by Application (2021-2026)
Table 37. North America Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$)
Table 38. North America Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020)
Table 39. North America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 40. North America PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020)
Table 41. North America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 42. North America PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020)
Table 43. Europe Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020)
Table 45. Europe PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 46. Europe PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020)
Table 47. Europe PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 48. Europe PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020)
Table 49. China Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$)
Table 50. China Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020)
Table 51. China PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 52. China PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020)
Table 53. China PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 54. China PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020)
Table 55. Japan Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020)
Table 57. Japan PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 58. Japan PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020)
Table 59. Japan PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 60. Japan PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020)
Table 63. Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020)
Table 65. Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020)
Table 67. India Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$)
Table 68. India Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020)
Table 69. India PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 70. India PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020)
Table 71. India PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 72. India PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020)
Table 73. Central & South America Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020)
Table 75. Central & South America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020)
Table 77. Central & South America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020)
Table 79. Merck Company Details
Table 80. Merck Business Overview
Table 81. Merck Product
Table 82. Merck Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 83. Merck Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Roche Company Details
Table 90. Roche Business Overview
Table 91. Roche Product
Table 92. Roche Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 93. Roche Recent Development
Table 94. AstraZeneca Company Details
Table 95. AstraZeneca Business Overview
Table 96. AstraZeneca Product
Table 97. AstraZeneca Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 98. AstraZeneca Recent Development
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Product
Table 102. Pfizer Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 103. Pfizer Recent Development
Table 104. GlaxoSmithKline Plc Company Details
Table 105. GlaxoSmithKline Plc Business Overview
Table 106. GlaxoSmithKline Plc Product
Table 107. GlaxoSmithKline Plc Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 108. GlaxoSmithKline Plc Recent Development
Table 109. Jiangsu HengRui Medicine Co.,Ltd Company Details
Table 110. Jiangsu HengRui Medicine Co.,Ltd Business Overview
Table 111. Jiangsu HengRui Medicine Co.,Ltd Product
Table 112. Jiangsu HengRui Medicine Co.,Ltd Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 113. Jiangsu HengRui Medicine Co.,Ltd Recent Development
Table 114. Innovent + Eli Lilly Business Overview
Table 115. Innovent + Eli Lilly Product
Table 116. Innovent + Eli Lilly Company Details
Table 117. Innovent + Eli Lilly Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 118. Innovent + Eli Lilly Recent Development
Table 119. Bristol Myers Squibb (BMS) Company Details
Table 120. Bristol Myers Squibb (BMS) Business Overview
Table 121. Bristol Myers Squibb (BMS) Product
Table 122. Bristol Myers Squibb (BMS) Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$)
Table 123. Bristol Myers Squibb (BMS) Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global PD-1 and PD-L1 Inhibitors Market Share by Type: 2020 VS 2026
Figure 2. PD-1 Inhibitors Features
Figure 3. PD-L1 Inhibitors Features
Figure 4. Global PD-1 and PD-L1 Inhibitors Market Share by Application: 2020 VS 2026
Figure 5. Advanced Melanoma Case Studies
Figure 6. Non-small Cell Lung Cancer (NSCLC) Case Studies
Figure 7. Renal Cell Carcinoma Case Studies
Figure 8. Bladder Cancer Case Studies
Figure 9. Others Case Studies
Figure 10. PD-1 and PD-L1 Inhibitors Report Years Considered
Figure 11. Global PD-1 and PD-L1 Inhibitors Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global PD-1 and PD-L1 Inhibitors Market Share by Regions: 2020 VS 2026
Figure 13. Global PD-1 and PD-L1 Inhibitors Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global PD-1 and PD-L1 Inhibitors Market Share by Players in 2019
Figure 16. Global Top PD-1 and PD-L1 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 and PD-L1 Inhibitors as of 2019
Figure 17. The Top 10 and 5 Players Market Share by PD-1 and PD-L1 Inhibitors Revenue in 2019
Figure 18. North America PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Merck Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 27. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Novartis Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 31. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. AstraZeneca Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 33. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Pfizer Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 35. GlaxoSmithKline Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. GlaxoSmithKline Plc Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 37. Jiangsu HengRui Medicine Co.,Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Jiangsu HengRui Medicine Co.,Ltd Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 39. Innovent + Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Innovent + Eli Lilly Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 41. Bristol Myers Squibb (BMS) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Bristol Myers Squibb (BMS) Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020)
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed